Degenerative disc disease (DDD) presents an autoimmune inflammation process with an expression of cytokines (interleukin [IL]-1β, tumor necrosis factor [TNF]-α, IL-6, IL-8, IL-17, and interferon [IFN] -γ) leading to increase the expression of aggrecenases and matrix-degrading proteases causing the destruction of disc tissue1,2,3,4. Deterioration of annulus fibrosis ends with formation of protrusion and disc herniation (DH). Prolapsing of nucleus pulposus shrinks the spinal canal leading to the secondary stenosis and spinal nerve compression. In this condition the inflammation process spreads around tissue and nerve. Beside the compression, inflamed spinal nerve will be pain generator per se with demonstration of motor deficit. Sometimes vertebrae’s listesis leads to foraminal stenosis and spinal nerve compression or ligament stretching being the main cause of the pain. Also, an inborn spinal canal stenosis worsens DDD symptoms and increases the probability of the surgery. The development of denervation process without reinnervation disables any conservative treatment tactics. Perhaps in the early stages of DDD the cellular therapy adding bioactive substances will have any opportunity to stop degeneration and, maybe, stimulate some regeneration, but never prevents from development of DH under abnormal biomechanical conditions. Several scientific works have been carried out related to Platelet-Rich Plasma (PRP) injection inside the disc9,10,11,12, but none has been reported about PRP injection or other cellular therapy at late stage. In this case report, two patients with sciatica and peripheral paresis due to DH, spinal canal stenosis and spinal nerve inflammation have been reported being saved from surgical intervention after local PRP injection.